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y 8, 2013.his study was designed to assess whether the reinforcement of the antioxidant system, through n-3 fatty acids plus
antioxidant vitamin supplementation, could reduce the incidence of post-operative atrial ﬁbrillation.Background Therapy to prevent post-operative atrial ﬁbrillation remains suboptimal. Although oxidative stress plays a key role in
the pathogenesis of this arrhythmia, antioxidant reinforcement has produced controversial results.Methods A total of 203 patients scheduled for on-pump cardiac surgery were randomized to placebo or supplementation
with n-3 polyunsaturated fatty acids (2 g/day) (eicosapentaenoic acid:docosahexaenoic acid ratio 1:2), vitamin C
(1 g/day), and vitamin E (400 IU/day). The primary outcome was the occurrence of post-operative atrial ﬁbrillation.
Secondary outcomes were the biomarkers related to oxidative stress and inﬂammation.Results Post-operative atrial ﬁbrillation occurred in 10 of 103 patients (9.7%) in the supplemented group versus 32 of 100
patients (32%) in the placebo group (p < 0.001). Early after surgery, placebo patients presented with increased
levels of biomarkers of inﬂammation and oxidative stress, which were markedly attenuated by antioxidant
supplementation. The activity of catalase, superoxide dismutase, and glutathione peroxidase in atrial tissue of the
supplemented patients was 24.0%, 17.1%, and 19.7% higher than the respective placebo values (p < 0.05). The
atrial tissue of patients who developed atrial ﬁbrillation showed NADPH oxidase p47-phox subunit protein and
mRNA expression 38.4% and 35.7% higher, respectively, than patients in sinus rhythm (p < 0.05).Conclusions This safe, well-tolerated, and low-cost regimen, consisting of n-3 polyunsaturated fatty acids plus vitamins C and E
supplementation, favorably affected post-operative atrial ﬁbrillation, increased antioxidant potential, and attenuated
oxidative stress and inﬂammation. (Prevention of Post-Operative Atrial Fibrillation: Pathophysiological
Characterization of a Pharmacological Intervention Based on a Novel Model of Nonhypoxic Pre-Conditioning;
ISRCTN45347268) (J Am Coll Cardiol 2013;62:1457–65) ª 2013 by the American College of Cardiology
FoundationAtrial ﬁbrillation following cardiac surgery is considered
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3; revised manuscript received June 18, 2013,for preventing post-operative atrial ﬁbrillation (POAF) are
suboptimal (2). Accumulated evidence suggests a role for
oxidative stress in ischemia-reperfusion injury (3–6).
Moreover, oxidative stress has been implicated in the
pathophysiology of several cardiovascular disorders (7–10).
Therefore, it is of interest to study speciﬁc biomarkers
derived from reactive oxygen species (ROS) for assessing
POAF risk (11). Speciﬁcally, atrial NADPH oxidase shows
increased activity during cardiac ischemia-reperfusion (6,12)
and is independently associated with increased risk for
POAF (13). Also, serum peroxide levels have been associ-
ated with POAF risk (14).
Interestingly, low to moderate ROS levels enhance the
endogenous antioxidant response (15) through activation
of nuclear factor erythroid 2–related factor 2 transcription
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1458factor (16). This mediator up-
regulates gene expression of car-
diomyocyte antioxidant enzymes
such as catalase (CAT) and glu-
tathione peroxidase (GSH-Px)
(17,18). Hence, n-3 polyunsatu-
rated fatty acids (n-3 PUFAs)
can act as indirect antioxidants
by inducing low to moderate
increases in ROS levels and de-
creasing vulnerability of myo-
cardial tissue to a subsequent
oxidative challenge.
Previously we proposed ahypothesis of nonhypoxic cardiac pre-conditioning to
patients scheduled for cardiac surgery (4). The paradigm
consists of a synergistic indirect antioxidant effect of n-3
PUFAs to elicit antioxidant enzyme induction followed by
the direct antioxidant effect of vitamins C and E. Some
clinical trials have used vitamins C and E to prevent POAF
(5,19,20) and to reduce early recurrence rates after electrical
cardioversion (21). n-3 PUFAs also have demonstrated
preliminary favorable effects with this aim (22–24). How-
ever, other similar studies (25–27) and the large multicenter
OPERA (Omega-3 Fatty Acids for Prevention of Post-
Operative Atrial Fibrillation) trial (28) clearly found no
evidence of a beneﬁcial effect of this treatment, thus giving
rise to a controversy (29–31). Therefore, the molecular bases
of this effect are needed to clarify these issues. An extended
background is presented in the Online Appendix.
The present study was aimed at testing the hypothesis
that reinforcement of the antioxidant system leads to a car-
dioprotective effect against the occurrence of POAF in
patients subjected to on-pump cardiac surgery.Methods
Design overview. This randomized, double-blind, placebo-
controlled trial was conducted in patients undergoing
on-pump cardiac surgery to test whether reinforcement of
their antioxidant status reduced the occurrence of POAF.
A population of 307 patients was admitted for cardiac
surgery at the University of Chile Clinical Hospital and
San Juan de Dios Hospital between February 2010 and
December 2011. The research protocol was approved by the
institutional ethics committees, according to the Helsinki
Declaration of the World Medical Association (2000). All
patients gave written informed consent.
Setting and participants. The patients were 18 years of age
or older, scheduled for coronary artery bypass graft, valve
surgery, or mixed, all in sinus rhythm (Fig. 1). Exclusion
criteria comprised a previous history of any arrhythmia,
previous myocardial infarction, current use of amiodarone or
sotalol, severe congestive heart failure (New York Heart
Association class III or IV), presence of prosthetic valves,
congenital valvular disease, or left atrial diameter >50 mm.We also excluded patients with conditions associated with
oxidative stress or inﬂammation such as chronic rheumatic
or neoplastic diseases, liver insufﬁciency, severe chronic
kidney disease (serum creatinine >2.0 mg/dl), and recent
infections. In addition, patients receiving nonsteroidal anti-
inﬂammatory drugs, corticosteroids, antioxidant vitamins, or
ﬁsh oil supplements 3 months prior to surgery were excluded.
Demographic and clinical characteristics were carefully recorded
(Table 1).
Randomization and interventions. Randomization of
participants to placebo or supplemented groups was per-
formed 7 days before surgery; the randomization was central,
nonstratiﬁed, block based (4-patient block size), and computer
generated. Surgical access was through a median sternotomy
incision, and the same induction and anesthesia protocol was
used for all patients. All anastomoses were sutured by hand.
Protection of myocardial tissue was accomplished with crys-
talloid cold potassium cardioplegic solution.
Treatment with n-3 PUFAs at a dose of 2 g daily was ini-
tiated immediately after randomization. The formulation
contained eicosapentaenoic (EPA) and docosahexaenoic
(DHA) acids in a 1:2 EPA:DHA ratio, as previously reported
(22). Two days before surgery, vitamin C (1 g/day) plus
vitamin E (400 IU/day) were added. The whole supplemen-
tation regimen continued until hospital discharge. The
placebo group received an equal number of identical capsules
containing caprylic/capric triglyceride (825 mg/capsule), inert
microgranules (500 mg), and vegetable oil (400 mg) replacing
the n-3 PUFAs, vitamin C, and vitamin E, respectively.
Outcomes and follow-up. The primary outcome of the
study was the occurrence of electrocardiographically (ECG)
conﬁrmed POAF from surgery until hospital discharge.
Continuous ECGmonitoring was performed 24 to 48 h after
the operation to detect new-onset atrial ﬁbrillation. Subse-
quently, a Holter monitoring device was placed on the
patients until the fourth post-operative day. Between the
removal of the Holter monitoring device and discharge, a 12-
lead ECG was performed every 12 h or whenever arrhythmia
symptoms occurred. The presence of ECG-documented
atrial ﬁbrillation for at least 1 min was recorded and
analyzed as “post-operative atrial ﬁbrillation.” All symp-
tomatic episodes detected by the patients or clinical residents
were conﬁrmed by a 12-lead ECG. The secondary outcomes
included oxidative stress–related biomarkers in atrial tissue/
plasma, as well as blood inﬂammation indexes. Blood
samples were drawn during the morning hours at a fasting
state on the day of enrollment (day 7), 5 days after n-3
PUFAs administration (day 2), 15 min before starting
extracorporeal circulation (time 0), 6 to 8 h after the surgical
operation (dayþ1), and post-operative day 5 (dayþ5). Right
atrial appendage samples were obtained immediately before
starting extracorporeal circulation. Sample management and
analysis methods are reported in the Online Appendix.
Statistical analyses. Sample size calculation was performed
for the primary outcome, with an expected POAF occur-
rence of 35% in the placebo group and 15% in the
Figure 1 Disposition of Patients
Randomization, treatment, and follow-up of participants.
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1459supplemented group, a signiﬁcance level of 0.05 and 80%
test power. The resulting sample size was 91 patients per
group (Stata version 10.1 for Windows; Stata Corporation,
College Station, Texas). The Shapiro-Wilk test and
distribution plots were used to test the normality of distri-
bution. The results are expressed as the mean  SD for
parametric variables and median plus interquartile range for
nonparametric variables. The signiﬁcant differences for
normally distributed variables were compared by Student t
test or repeated-measures analysis of variance, and the post-
hoc Bonferroni test was applied. The signiﬁcant differences
for nonnormally distributed variables were compared using
the Mann-Whitney U test. Categorical variables are ex-
pressed as numbers and frequencies (%). The Fisher exact
test with Katz approximation was used to compare adverse
event frequencies. The primary analysis, based on conﬁrmed
atrial ﬁbrillation events, was by intention to treat, including
all patients according to treatment assigned at randomiza-
tion, independently of the duration of treatment and the
follow-up period. Time-to-ﬁrst-event analysis was calcu-
lated by the Kaplan-Meier method and compared using
the log-rank test. Cox proportional hazards models with
the Breslow method for ties were used to calculate the
hazard ratio in the survival curves between the groups.
The Spearman rank-order coefﬁcient was estimated incorrelation analysis. All reported p values are 2-sided. The
difference between the groups was considered signiﬁcant
with a p value <0.05. Statistical analysis was performed
using Stata version 10.1 (Stata Corporation).Results
Primary outcomes. The study population consisted of 203
patients with comparable baseline characteristics (Table 1).
POAF occurred in 10 of 103 patients (9.7%) of the sup-
plemented group versus 32 of 100 patients (32%) of the
placebo group (relative risk [RR]: 0.28; 95% CI: 0.14 to
0.56; p < 0.001). The Kaplan-Meier survival curves illus-
trate the occurrence of POAF (Fig. 2). The 30 patients
(71.4%) who developed atrial ﬁbrillation between the
second and third post-operative days belonged mostly to the
placebo group (24 of 30 patients [80%]; log-rank test
p < 0.001). The mean time of POAF occurrence was 3.3 
0.7 days in patients assigned to the supplementation group
and 2.9  0.4 days in the placebo group. The placebo
patients had 3.62 times more risk for POAF at any day
compared with the supplemented patients (hazard ratio:
3.62; 95% CI: 1.78 to 7.36; p < 0.001). The number
needed to treat to prevent one atrial ﬁbrillation event was
4.7 patients (95% CI: 3.3 to 11.4). POAF was diagnosed in
Table 1 Baseline Characteristics of Enrolled Patients
Characteristic
Placebo
(n ¼ 100)
Supplemented
(n ¼ 103) p Value
Age, yrs 58.5 (56.6–61.0) 61 (58.0–62.0) 0.438
Male 88 (88.0) 85 (82.5) 0.272
Body mass index, kg/m2 24.8 (23.9–25.6) 25.4 (24.6–26.2) 0.439
Pre-operative heart rate on resting, beats/min 73 (70–74) 75 (73–77) 0.428
Post-operative heart rate (day þ1), beats/min 63 (59–65) 61 (58–63) 0.595
Pre-operative systolic blood pressure, mm Hg 127 (124–131) 131 (127–134) 0.567
Pre-operative diastolic blood pressure, mm Hg 78 (75–81) 74 (71–79) 0.775
Left ventricular ejection fraction, % 55 (55–59) 55 (55–60) 0.474
Left atrial AP dimension, mm 39.6 (37.1–41.0) 40 (39.2–43.1) 0.454
Comorbidities
Systemic hypertension 29 (29.0) 32 (31.0) 0.748
Diabetes mellitus 57 (57.0) 62 (60.2) 0.644
Hypercholesterolemia 45 (45.0) 47 (45.6) 0.928
Smoking history 36 (36.0) 39 (37.9) 0.783
Chronic obstructive pulmonary disease 11 (11.0) 13 (12.6) 0.830
NYHA functional class I 45 (45.0) 48 (46.6) 0.901
NYHA functional class II 17 (17.0) 12 (11.6) 0.428
Coronary artery disease
1 compromised vessel 5 (5.0) 6 (5.8) 0.978
2 compromised vessels 26 (26.0) 24 (23.3) 0.754
3 compromised vessels 33 (33.0) 40 (38.8) 0.587
4 compromised vessels 3 (3.0) 4 (3.9) 0.521
Valvular dysfunction
Mitral stenosis 25 (25.0) 24 (23.3) 0.874
Mitral regurgitation 14 (14.0) 12 (11.7) 0.682
Aortic stenosis 8 (8.0) 7 (6.8) 0.795
Other valvulopathy 5 (5.0) 5 (4.9) 0.618
Perioperative features
Revascularization 48 (48.0) 55 (53.4) 0.484
Valve replacement 33 (33.0) 29 (28.2) 0.542
Mixed etiology 19 (19.0) 19 (18.4) 1.000
Cross-clamp time, min 79 (75.0–95.0) 78 (71.1–85.0) 0.571
CPB time, min 92 (87.0–97.0) 89 (87.0–94.9) 0.515
Pharmacological treatment
Aspirin 69 (69.0) 68 (66.0) 0.650
Atorvastatin 37 (37.0) 37 (35.9) 0.873
Other statins 11 (11.0) 6 (5.8) 0.169
ACE inhibitors 54 (54.0) 67 (65.0) 0.109
ARBs 21 (21.0) 19 (18.4) 0.647
Diuretics 25 (25.0) 28 (27.2) 0.723
Beta-blockers 64 (64.0) 61 (59.2) 0.484
Inhibitors of platelet aggregation 12 (12.0) 7 (6.8) 0.122
Calcium channel blockers 7 (7.0) 9 (8.7) 0.646
Nitrates 2 (2.0) 3 (2.9) 0.675
Insulin 3 (3.0) 2 (1.9) 0.627
Sulfonylurea 7 (7.0) 10 (9.7) 0.486
Biguanides 25 (25.0) 29 (28.2) 0.611
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting enzyme; AP ¼ anteroposterior; ARB ¼ angiotensin receptor blocker; CPB ¼ cardiopulmonary bypass; NYHA ¼ New
York Heart Association.
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1460the coronary or intensive care unit in 6 patients (60%) in the
supplemented group and in 14 patients (43.7%) in the
placebo group (p ¼ 0.758). The remaining cases were
detected by means of Holter monitoring (after discharge
from the intensive care unit, a Holter monitoring device was
placed until day 4) or by ECG recordings. The meanduration of POAF was 10.8  0.7 h in patients assigned to
supplementation and 11.2  1.5 h in the placebo patients
(p ¼ 0.06). The length of stay in the intensive care unit and
in the hospital was 2.87  0.44 versus 3.08  0.54 days
(p ¼ 0.76) and 8.77  0.37 versus 9.57  0.66 days
(p < 0.05) for the supplemented versus placebo groups,
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1461respectively. Spontaneous conversion to sinus rhythm
without any intervention occurred in 3 supplemented
patients and 4 placebo patients developing atrial ﬁbrillation
(Fisher exact test p ¼ 0.20). Cardioversion with amiodarone
was achieved in 5 supplemented and 25 placebo patients
(Fisher exact test p ¼ 0.096). Electrical cardioversion was
successfully performed in 2 supplemented and 3 placebo
patients (Fisher exact test p ¼ 0.340). There were no
signiﬁcant differences in therapy drugs in both groups
between pre-operative and post-operative data; however,
beta-blocker dose showed an expectable trend of being
increased in both groups, rising from 64% to 71% in the
placebo group (Fisher exact test p¼ 0.361) and from59.2% to
71.8% in the supplemented group (Fisher exact test
p¼ 0.438). The frequency of use of beta-blockers in the post-
operative period did not show a statistically signiﬁcant
difference between the groups (Fisher exact test p ¼ 0.521).
Secondary outcomes. OXIDATIVE STRESSANDINFLAMMATION-
RELATED BIOMARKERS. Oxidative stress biomarkers, including
lipid peroxidation assessed as malondialdehyde (MDA) levels
in blood throughout the protocol and atrial tissue on the day
of surgery (time 0), are illustrated in Figures 3A and 3B,
respectively. After 5 days of n-3 PUFA exposure, the MDA
levels were 59.6% higher than baseline values (p < 0.01) andFigure 2 Freedom From Atrial Fibrillation
The Kaplan-Meier survival curve depicts the occurrence of post-operative atrial ﬁbrillation
POAF ¼ post-operative atrial ﬁbrillation.45.6% higher than placebo values (p < 0.01). However, there
was no signiﬁcant difference in MDA levels at time 0 following
the addition of antioxidant vitamins. Early after surgery
(day þ1), the placebo group exhibited 47.5% higher MDA
levels than the supplemented group, with the levels being
3.7-fold and 3.5-fold greater than the baseline (day 7) and
pre-operative (time 0) values, respectively (p < 0.01). The
supplemented group presented 2.8-fold and 2.2-fold increased
plasma levels of MDA compared with the baseline (day 7)
and pre-operative (time 0) values, respectively (p < 0.01)
(Fig. 3A). The supplemented group presented 26.1% lower
MDA levels (p < 0.01) in atrial tissue on the day of surgery
compared with the placebo group (Fig. 3B). The correlation
between plasma and atrial tissue lipid peroxidation at the time of
surgery is depicted in Figure 3C. Interestingly, these 2 variables
demonstrated a strong direct correlation in both the placebo
(r ¼ 0.96; p < 0.01; n ¼ 50) and supplemented (r ¼ 0.88;
p < 0.01; n ¼ 50) groups, with no signiﬁcant differences
between the groups. In addition, patients who suffered
POAF presented with signiﬁcantly higher levels of atrial MDA
(4.47 vs. 3.85 mmol/mg protein; p < 0.01) at the time of
surgery, compared with patients who did not develop POAF.
Inﬂammation-related variables throughout the protocol
are shown in Figures 3D and 3E.following cardiac surgery in the placebo and supplemented groups.
Figure 3
Oxidative Stress and Inﬂammation Biomarkers in Blood Throughout the Protocol and Lipid Peroxidation in Atrial Tissue
on the Day of Surgery
(A) Oxidative stress in blood assessed by malondialdehyde (MDA) concentration (n ¼ 50 for each group). (B) Oxidative stress in atrial tissue (time 0), assessed by MDA
concentration (n ¼ 50 for each group). (C) Scatter diagram shows the Spearman correlation of MDA concentration in plasma versus atrial tissue. (D) Plasma high-sensitivity
C-reactive protein (hs-CRP) levels for supplemented and placebo patients (n ¼ 50 for each group). (E) Blood leukocyte counts throughout the protocol for supplemented and
placebo patients (n ¼ 50 for each group). *p < 0.01 versus placebo. yp < 0.01 versus baseline. zp < 0.01 versus pre-operative. xp < 0.05 versus placebo. kp < 0.05 versus
baseline. {p < 0.05 versus pre-operative. Day 7 ¼ moment of starting n-3 polyunsaturated fatty acid supplementation or placebo. Day 2 ¼ moment of starting the anti-
oxidant vitamin supplementation or placebo. Time 0 ¼ day of surgery. Day þ1 ¼ 6 to 8 h after surgery. Day þ5 ¼ post-operative ﬁfth day.
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1462Early after surgery (day þ1), the placebo and supple-
mented groups presented higher serum high-sensitivity C-
reactive protein levels, 3.6-fold and 2.2-fold greater than the
pre-operative values (p < 0.01). However, the supplemented
group exhibited values 35.4% lower than those of the
placebo group (p < 0.05) (Fig. 3D). Following 5 days of n-3
PUFA treatment (day 2), the leukocyte count in the
supplemented group was 32.5% higher than the baseline
values (p < 0.05). Early after surgery (day þ1), the placebo
and supplemented groups presented a 73.8% and 36.2%
increase in leukocyte count, respectively, compared with pre-
operative values (p < 0.05). In addition, the leukocyte count
in the supplemented group at this time was 22.2% lower
than that in the placebo group (p < 0.05) (Fig. 3E).
CHARACTERIZATION OF ATRIAL TISSUE REDOX STATUS ON DAY
OF SURGERY. The activity and mRNA expression of the
antioxidant enzymes CAT, superoxide dismutase (SOD),
and GSH-Px in the atrial tissue of supplemented and
placebo patients on the day of surgery are presented in
Figures 4A, 4B, and 4C. The activity of antioxidant
enzymes CAT, SOD, and GSH-Px in the atrial tissue of the
supplemented patients was 24.0%, 17.1%, and 19.7% higher
than the respective placebo values (p < 0.05). Accordingly,
the assessment of enzyme gene expression levels in the
supplemented group indicated 52.9%, 42.5%, and 34.5%
higher levels, respectively, compared with the placebo group
(p < 0.01).The p47-phox NADPH oxidase subunit protein and
mRNA expression in atrial tissue are shown in Figures 4D
and 4E. Patients with POAF presented 115.5% higher
protein expression and 65.8% higher mRNA levels (Fig. 4D)
of this subunit compared with patients in sinus rhythm
(p < 0.05). In addition, the supplemented group presented
protein expression and mRNA levels 41.3% and 36.4%
lower than the respective placebo group values (p < 0.05)
(Fig. 4E).
Further results concerning plasma oxidative stress–related
biomarkers, erythrocyte thiol index, and atrial tissue
xanthine oxidase (XO) activity plus nuclear factor kappaB
(NF-kappaB) Western blot and electrophoretic mobility
shift assay analyses are shown in Online Figures 1 and 2,
respectively. A detailed explanation of these data is also
presented in the Online Appendix.
Adverse events. Adverse events occurred in 7 supple-
mented and 7 placebo patients, with no signiﬁcant differ-
ences as determined by Fisher exact test (RR: 0.97; 95%
CI: 0.35 to 2.67; p ¼ 0.586). The most frequent events were
dyspepsia (4 vs. 3 events; RR: 1.58; 95% CI: 0.34 to 6.76;
p ¼ 0.71) and diarrhea (3 vs. 4 events; RR: 0.44; 95%
CI: 0.21 to 2.73; p ¼ 0.47). One patient of the supple-
mented group withdrew consent. No hemorrhagic or major
adverse cardiovascular events were observed during the
hospital follow-up. No patients died during the hospital
follow-up; however, during the following 6 months after
discharge, 8 patients died (5 supplemented vs. 3 placebo;
Figure 4
Characterization of Atrial Tissue Antioxidant Enzymes (CAT, SOD, and GSH-Px) in Supplemented and Placebo Groups and
Pro-Oxidant Enzymes (NADPH Oxidase) Proﬁle on the Day of Surgery (Time 0)
Comparison between supplemented versus placebo plus atrial ﬁbrillation versus sinus rhythm patients. (A) Catalase (CAT) enzyme activity and mRNA expression (n ¼ 50 for
each group). (B) Superoxide dismutase (SOD) enzyme activity and mRNA expression (n ¼ 50 for each group). (C) Glutathione peroxidase (GSH-Px) enzyme activity and mRNA
expression (n ¼ 50 for each group). (D) Association between the occurrence of atrial ﬁbrillation and NADPH oxidase p47-phox subunit protein and mRNA expression (n ¼ 6 for
each group). (E) NADPH p47-phox subunit protein and mRNA expression in supplemented versus placebo groups (n ¼ 12 for each group). *p < 0.05 versus placebo. yp < 0.01
versus placebo. zp < 0.05 versus sinus rhythm. xp < 0.01 versus atrial ﬁbrillation. AF(þ) ¼ atrial ﬁbrillation; AF() ¼ sinus rhythm.
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1463RR: 1.63; 95% CI: 0.40 to 6.65; p ¼ 0.37), representing
a mortality rate of 3.94% of the randomized patients.
Discussion
This study demonstrated that a novel strategy of antioxidant
reinforcement was effective against POAF, as previously
hypothesized (4,6). The combination of indirect antioxidant
effects of n-3 PUFAs plus direct antioxidant effects of
vitamins C and E decreased the vulnerability of atrial tissue
to develop arrhythmia, showing a noteworthy 66% reduc-
tion. Through assessment of oxidative stress and inﬂam-
mation biomarkers, we determined the contribution of these
processes throughout the study protocol. The increasedROS status induced by n-3 PUFAs was conﬁrmed on
day 2 in the supplemented group by the elevation of
plasma MDA levels (Fig. 3A), as well as the reduction of
either ferric-reducing ability of plasma or erythrocyte thiol
index (Online Figs. 1A and 1B, respectively). Early after
surgery, lipid peroxidation (Fig. 3A) and inﬂammation
biomarker levels (Figs. 3D and 3E) increased signiﬁcantly in
both groups but less markedly in the supplemented group.
Interestingly, this response could be due to increased
ROS depuration and scavenging, as well as decreased ROS
production. Themolecular bases supporting this view could be
related to the metabolic status of atrial tissue. The supple-
mented group showed up-regulation of CAT, SOD, and
GSH-Px activity and mRNA expression, accounting for an
Rodrigo et al. JACC Vol. 62, No. 16, 2013
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1464improvement in the ability of atrial tissue to depurate ROS, an
effect attributable to n-3 PUFA exposure. In addition, the
ﬁnding of decreased protein and mRNA expression of the
NADPH oxidase p47-phox subunit in the supplemented
group (Fig. 4E) might be due to down-regulation of this
enzyme activity following vitamin C and E exposure, consis-
tent with studies of the aorta in a rat model (32). Remarkably,
the higher expression of this enzyme subunit in patients
developing atrial ﬁbrillation (Fig. 4D) strongly supports
a pathogenetic role of oxidative stress, as reported in experi-
mentalmodels (33). Previous trials demonstrated that patients
experiencing POAF exhibit higher pre-operative NADPH
oxidase activity (13). Although a recent study failed to
demonstrate a beneﬁcial effect of vitamin C supplementation
on POAF (34), it should be stressed that vitamin C could
enhance its antioxidant potential administered together with
vitaminEbecause both act synergistically (5,20,35).We found
detectable atrial XO activity, another enzyme contributing to
superoxide production (12), thatwas not signiﬁcantly different
between supplemented and placebo groups but was higher in
patients with POAF compared with those in sinus rhythm
(Online Figs. 1C and 1D). Enhanced XO activity should be
expected following ischemia-reperfusion, but we determined
this activity only at the onset of the surgical procedure.
Concerning n-3 PUFA supplementation, all randomized
placebo-controlled studies that failed to demonstrate a beneﬁ-
cial effect used a formulation containing 1.24 EPA:DHA
ratio (25–28). In contrast, data reported here were obtained
with anEPA:DHA ratio equal to 0.5. Clinical trials performed
with this sameEPA:DHA ratio also reported a beneﬁcial effect
in POAF prevention (22–24), although of a lesser magnitude.
This difference could be due to the additional effect of vitamins
C and E in our study. In support of the present data, a meta-
regression analysis showed a trend toward a beneﬁt from n-3
PUFA supplementation when the EPA:DHA ratio was 0.5
(36). More recently, a study including all published controlled
trials concluded that n-3 PUFA therapy decreased the risk
of developing POAF in post-surgical cardiac patients (37).
The molecular mechanism accounting for the effectiveness
of this EPA:DHA ratio remains to be determined, but it could
be related to the kinetics of incorporation of these fatty acids
into cell membranes. A previous incorporation study in
human atrial tissue indicated a more rapid incorporation for
DHA than EPA, reaching the DHA half-maximal incorpo-
ration during the ﬁrst week of ﬁsh oil supplementation (38).
Notably, our study reported a greater preventive effect against
POAF compared with other previous attempts for this
purpose. Possibly these results arose from the pleiotropic
effects of n-3 PUFAs administered in an optimal 1:2
EPA:DHA ratio plus the direct antioxidant effects of vita-
mins C and E. Furthermore, our data support the role of
oxidation and inﬂammation in the pathophysiology of POAF.
Study limitations. The study population showed a male
predominance, with younger patients compared with other
related studies. We did not assess n-3 PUFA pleiotropic
effects other than those related to oxidative stress andinﬂammation. Therefore, we cannot rule out that additional
antiarrhythmic mechanisms are operative in this setting.
Given that continuous monitoring was performed only
until the fourth post-operative day, some asymptomatic
arrhythmia episodes after that day may have been undetected.
Conclusions
This study presented a strategy that successfully reduced the
occurrence of POAF based on an indirect antioxidant effect of
n-3 PUFAs (1:2 EPA:DHA ratio) plus a direct antioxidant
effect of vitamins C and E. Oxidative stress amelioration was
accompanied by a reduction in the vulnerability of myocardial
tissue to the oxidative challenge known to occur during
ischemia-reperfusion of this clinical model. This short-term,
safe, low-cost treatment containing readily available sub-
stances represents a cost-effective strategy that could improve
the outcome of patients who undergo on-pump cardiac sur-
gery, as well as other surgeries, involving atrial ﬁbrillation risk,
thereby reducing major cardiovascular adverse events, the
length of hospital stay, and the overall cost.Acknowledgments
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